Multiple Myeloma Drugs Brought To Market - Myeloma Drug Therapies

Drugs brought to market

The MMRF and MMRC have helped bring ten drugs to market in the time it normally takes for one. We currently have dozens of treatments in the pipeline, including those that target genomic markers, immunotherapies and antibodies and novel agents and mechanisms.


Immunotherapy is the newest approach to multiple myeloma treatment. It is an umbrella term that describes different ways to stimulate the immune system and enhance its ability to attack cancer cells. Many of these treatments involve antibodies that target specific proteins found on multiple myeloma cells themselves or on immune cells, while others include vaccines and modified immune cells.

Darzalex™ (daratumumab)

is the first monoclonal antibody approved for use in Multiple Myeloma. It is recommended for use in the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent (IMiD), or who are refractory to both a proteasome inhibitor and an IMiD.


Empliciti® (elotuzumab)

The U.S. Food and Drug Administration granted approval for Empliciti® (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.


Proteasome Inhibitors

By blocking the mechanism of the proteasome, which degrades unwanted cellular proteins, the inhibitors create a build up of these proteins in the cell and cause the cancer cells to die. Learn more about proteasome inhibitors.

Velcade (bortezomib)

Velcade® (bortezomib) was the first drug to validate the proteasome as a therapeutic target. It is used across the entire spectrum of myeloma disease, given as an injection under the skin (subcutaneously) or intravenously.


Kyprolis® (carfilzomib)

A newer proteasome inhibitor, Krypolis is approved for use in patients with relapsed/refractory myeloma. It is being studied in other types of patients.


Ninlaro® (ixazomib)

The U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib). Ninlaro is the first oral proteasome inhibitor and is approved in combination with Revlimid (lenalidomide) and dexamethasone.


Immunomodulatory Agents (IMiDs)

IMiDs are thalidomide analogues, which possess pleiotropic anti-myeloma properties including immune-modulation, anti-angiogenic, anti-inflammatory and anti-proliferative effects. Learn more about IMiDs

Thalomid® (thalidomide)

This drug was shown to be effective across the spectrum of myeloma disease; peripheral neuropathy (nerve problems) is a common side effect and can be irreversible. It is infrequently used in the US.


Revlimid® (lenalidomide)

Revlimid® is an oral immunomodulatory agent that is similar to Thalomid® (thalidomide) but is more potent. It is also used to treat other diseases (myelodysplastic syndrome and mantle cell lymphoma).


Pomalyst® (pomalidomide)

Pomalyst® is an oral immunomodulatory agent that is similar to Revlimid® (lenalidomide) and Thalomid® (thalidomide) but is more potent with fewer side effects.


Epigenetic Agents

Epigenetics are heritable changes in gene activity and expression that occur without alteration in DNA sequence. A common type of epigenetic alteration in cancer involves aberrant changes in chromosomal proteins called histones. Epigenetic targeted therapeutics are thought to work in part by reversing some cancer-associated epigenome modifications. Learn more about epigenetic agents.

Farydak® (panobinostat)

Farydak® is a histone deacetylase inhibitor that is administered in combination with Velcade® (bortezomib) and dexamethasone. It is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. This indication was approved by the FDA on February 23, 2015 under accelerated approval based on progression free survival.


Cytotoxic Chemotherapy

Chemotherapy is the use of anti-cancer (Cytotoxic) drugs to destroy cancer cells. The drugs enter the bloodstream and are distributed to all parts of the body. They destroy cancer cells by interfering with their ability to divide and grow. Learn more about cytotoxic chemotherapy.


Doxil is a reformulated version of doxorubicin (Adriamycin®), a cancer drug that has been used for many years in traditional chemotherapy regimens in multiple myeloma.


Drugs Currently In Development

The MMRF is actively investigating a number of promising new compounds. We currently have multiple trials opened for Immunotherapies, Targeted Therapies and Novel Agents & Mechanisms, you can view them here.

From the MMRF Knowledge Center, learn more about:

Multiple Myeloma Drug Classifications
Approved Multiple Myeloma Drugs
Experimental Multiple Myeloma Drugs